Literature DB >> 24692062

The automated radiosynthesis and purification of the opioid receptor antagonist, [6-O-methyl-11C]diprenorphine on the GE TRACERlab FXFE radiochemistry module.

Michael Fairclough1, Christian Prenant, Gavin Brown, Adam McMahon, Jonathan Lowe, Anthony Jones.   

Abstract

[6-O-Methyl-(11)C]diprenorphine ([(11)C]diprenorphine) is a positron emission tomography ligand used to probe the endogenous opioid system in vivo. Diprenorphine acts as an antagonist at all of the opioid receptor subtypes, that is, μ (mu), κ (kappa) and δ (delta). The radiosynthesis of [(11)C]diprenorphine using [(11)C]methyl iodide produced via the 'wet' method on a home-built automated radiosynthesis set-up has been described previously. Here, we describe a modified synthetic method to [(11)C]diprenorphine performed using [(11)C]methyl iodide produced via the gas phase method on a GE TRACERlab FXFE radiochemistry module. Also described is the use of [(11)C]methyl triflate as the carbon-11 methylating agent for the [(11)C]diprenorphine syntheses. [(11)C]Diprenorphine was produced to good manufacturing practice standards for use in a clinical setting. In comparison to previously reported [(11)C]diprenorphine radiosyntheisis, the method described herein gives a higher specific activity product which is advantageous for receptor occupancy studies. The radiochemical purity of [(11)C]diprenorphine is similar to what has been reported previously, although the radiochemical yield produced in the method described herein is reduced, an issue that is inherent in the gas phase radiosynthesis of [(11)C]methyl iodide. The yields of [(11)C]diprenorphine are nonetheless sufficient for clinical research applications. Other advantages of the method described herein are an improvement to both reproducibility and reliability of the production as well as simplification of the purification and formulation steps. We suggest that our automated radiochemistry route to [(11)C]diprenorphine should be the method of choice for routine [(11)C]diprenorphine productions for positron emission tomography studies, and the production process could easily be transferred to other radiochemistry modules such as the TRACERlab FX C pro.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  [11C]diprenorphine; automated radiosynthesis; methyl triflate; opioid receptors; positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 24692062     DOI: 10.1002/jlcr.3194

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  5 in total

1.  Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

Authors:  Shefali Srivastava; Emily A Fergason-Cantrell; Roger I Nahas; John R Lever
Journal:  Tetrahedron       Date:  2016-08-04       Impact factor: 2.457

Review 2.  Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.

Authors:  János Marton; Anikó Fekete; Paul Cumming; Sándor Hosztafi; Pál Mikecz; Gjermund Henriksen
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

3.  Striatal opioid receptor availability is related to acute and chronic pain perception in arthritis: does opioid adaptation increase resilience to chronic pain?

Authors:  Christopher A Brown; Julian Matthews; Michael Fairclough; Adam McMahon; Elizabeth Barnett; Ali Al-Kaysi; Wael El-Deredy; Anthony K P Jones
Journal:  Pain       Date:  2015-11       Impact factor: 7.926

4.  Radiosynthesis and reactivity of N-[11C]methyl carbamoylimidazole.

Authors:  Manikandan Kadirvel; Déborah Cardoso; Sally Freeman; Gavin Brown
Journal:  J Radioanal Nucl Chem       Date:  2018-06-19       Impact factor: 1.371

Review 5.  A Survey of Molecular Imaging of Opioid Receptors.

Authors:  Paul Cumming; János Marton; Tuomas O Lilius; Dag Erlend Olberg; Axel Rominger
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.